Palmoplantar Cutaneous Reaction to Sorafenib
نویسندگان
چکیده
منابع مشابه
[Palmoplantar cutaneous reaction to sorafenib].
Sorafenib is a new oral drug currently approved for the treatment of metastatic renal cell carcinoma and hepatocellular carcinoma. The drug acts partly by inhibiting the tyrosine kinase receptors implicated in angiogenesis and tumor progression, and partly by blocking Raf kinase pathways. Up to 90% of patients receiving this treatment are reported to develop dermatological sideeffects. Hyperker...
متن کاملCutaneous reaction due to ctenocephalides felis felis: a case report
Introduction: Fleas are small, blood-sucking insects that can transmit some pathogens to human and animals. Case Report: This paper presents a 21-year-old woman with severe skin reactions in her right forearm. After initial examinations, the symptoms were recognized as skin reaction caused by the bite of some human blood-sucking insects. Finally, after 15 days of flea bites, the symptoms wer...
متن کاملCutaneous mucinosis in a patient taking ustekinumab for palmoplantar psoriasis.
Discrete papular lichen myxedematosus (DPLM), asubset of localized lichen myxedematosus, is a rarecutaneous mucinosis of unknown etiology. We reporta case of a 57-year-old woman with palmoplantarpsoriasis who developed DPLM 8 weeks after addingustekinumab to a long-term course of methotrexate.The patient had previously failed 2 prior tumor necrosisfactor (TNF) inhibitors, adalimumab and etanerc...
متن کاملA rare adverse reaction of sorafenib
Sorafenib is a multikinase inhibitor thought to target vascular endothelial growth factor and its receptor. The European Medicines Agency (EAMA) and Food and Drug Administration (FDA) approved the use of sorafenib in late-stage hepatic cellular cancer (HCC) on October 30, 2007, and November 19, 2007, respectively. It is the only drug approved for use in the systematic treatment of primary HCC, ...
متن کاملSorafenib Induces Delayed-Onset Cutaneous Hypersensitivity: A Case Series
Sorafenib is an oral multikinase inhibitor with clinical activity against hepatocellular carcinoma (HCC) and renal cell carcinoma. Administration of sorafenib carries a variety of adverse cutaneous reactions. Common adverse effects induced by sorafenib include hand-foot skin reactions, facial erythema, splinter subungual hemorrhage, and alopecia. Although erythema multiforme (EM) related to sor...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Actas Dermo-Sifiliográficas (English Edition)
سال: 2009
ISSN: 1578-2190
DOI: 10.1016/s1578-2190(09)70165-9